EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman

Najah Abdullah Al-salmi, Bushra Salman, Yaman Walid Kassab, Shireen Imam Bakhsh Al Zadjali, Mullaicharam Bhupathyraaj, Zainab Ali Al Lawati, Murtadha Al-Khabori, Salam AL-Kindi

Journal of the Oman Medical Association · 05.05.2026 · 3 (1) · 7

DOI: 10.3390/joma3010007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Oman Medical Association, online erschienen am 05.05.2026. Verfasst von Najah Abdullah Al-salmi und 7 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myeloproliferative neoplasms (MPNs)—including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)—are clonal stem-cell disorders driven by JAK–STAT pathway activation within an inflammatory microenvironment. Ruxolitinib (RUX), a JAK1/2 inhibitor, improves splenomegaly and symptom burden in myelofibrosis and serves as second-line therapy in hydroxyurea-resistant/intolerant PV. However, real-world data from Middle Eastern populations remains scarce. This study evaluates the effectiveness, safety, and dosing practices of RUX in a heterogeneous Omani MPN cohort.

Methods

Electronic records were reviewed for adults diagnosed with MF, PV, or ET who received RUX at Sultan Qaboos University Hospital or the National Hematology and BMT Center between 2018 and 2025. Only patients with at least six months of follow-up were included. Clinical variables, laboratory results, dosing information, and data on treatment responses and toxicities were extracted. Outcomes focused on spleen size changes, symptom improvement, hematologic responses, adverse events, and reasons for treatment discontinuation.

Results

Twenty-eight patients were included (71% PMF; mean age 52.6 years). The median time from diagnosis to RUX initiation was 28 months. Among MF patients, mean spleen size decreased by 35% (p = 0.003); 28% achieved ≥35% reduction. Symptomatic improvement was reported by 60%. LDH levels remained unchanged. PV patients showed spleen control in 75% and symptom benefit in all cases, while ET responses were limited. Cytopenias (21%) and infections (11%) were the most common toxicities; discontinuation occurred in 8/28 of patients, and two patients died while on therapy. Initial dosing was frequently inappropriate, particularly underdosing in MF and overdosing in PV.

Conclusions

RUX provided meaningful spleen and symptom improvement in MF and PV; however, toxicity, delayed initiation, and inconsistent dosing practices limited overall outcomes. Enhanced guideline-based dosing, proactive toxicity management, and structured multidisciplinary follow-up are essential to optimize RUX use in regional MPN practice.

Zitieren

APA

Al-salmi, N. A., Salman, B., Kassab, Y. W., Zadjali, S. I. B. A., Bhupathyraaj, M., Lawati, Z. A. A., Al-Khabori, M., & AL-Kindi, S. (2026). Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman. Journal of the Oman Medical Association, 3(1), 7. https://doi.org/10.3390/joma3010007

Vancouver

Al-salmi NA, Salman B, Kassab YW, Zadjali SIBA, Bhupathyraaj M, Lawati ZAA, et al. Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman. Journal of the Oman Medical Association. 2026;3(1):7. doi:10.3390/joma3010007

BibTeX
@article{Alsalmi2026,
  author = {Al-salmi, Najah Abdullah and Salman, Bushra and Kassab, Yaman Walid and Zadjali, Shireen Imam Bakhsh Al and Bhupathyraaj, Mullaicharam and Lawati, Zainab Ali Al and Al-Khabori, Murtadha and AL-Kindi, Salam},
  title = {Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman},
  journal = {Journal of the Oman Medical Association},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {7},
  doi = {10.3390/joma3010007}
}
Kostenlos starten →